SEC Tracker
Get the app

BridgeBio Pharma BBIO

A Valantine Hannah (Director) plans to sell 8,671 BBIO shares, about $624,312

Form
144
Filed
Importance
Routine
  1. Approximate sale date: Mar 10, 2026
  2. Broker: Morgan Stanley Smith Barney LLC Executive Financial Services
  3. Shares acquired by: Stock Option Exercise
  4. 10b5-1 plan adopted: Nov 14, 2025

All of A Valantine Hannah's insider filings, holdings and planned sales

Written from the Form 144 on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when BridgeBio Pharma files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Biomarin Pharmaceutical BMRN public float $6.7B, Jun 30, 2025
  2. Revolution Medicines RVMD public float $6.7B, Jun 30, 2025
  3. Jazz Pharmaceuticals JAZZ public float $6.3B, Jun 30, 2025
  4. Corcept Therapeutics CORT public float $6.1B, Jun 30, 2025
  5. Repligen RGEN public float $6.0B, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.